Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma

Nicola Amodio, Maria Teresa Di Martino, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone

Research output: Contribution to journalArticle

Abstract

Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
Volume13
Issue numberSUPPL.1
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Untranslated RNA
Multiple Myeloma
Expert Testimony
Biomarkers
Hematologic Neoplasms
MicroRNAs
Therapeutics
Neoplasms

Keywords

  • MicroRNA
  • MiRNA
  • MiRNA therapeutics
  • Multiple myeloma
  • Non coding RNA

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Non-coding RNA : A novel opportunity for the personalized treatment of multiple myeloma. / Amodio, Nicola; Di Martino, Maria Teresa; Neri, Antonino; Tagliaferri, Pierosandro; Tassone, Pierfrancesco.

In: Expert Opinion on Biological Therapy, Vol. 13, No. SUPPL.1, 06.2013.

Research output: Contribution to journalArticle

Amodio, Nicola ; Di Martino, Maria Teresa ; Neri, Antonino ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco. / Non-coding RNA : A novel opportunity for the personalized treatment of multiple myeloma. In: Expert Opinion on Biological Therapy. 2013 ; Vol. 13, No. SUPPL.1.
@article{36847bd773294522ab423bc241d90bf3,
title = "Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma",
abstract = "Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.",
keywords = "MicroRNA, MiRNA, MiRNA therapeutics, Multiple myeloma, Non coding RNA",
author = "Nicola Amodio and {Di Martino}, {Maria Teresa} and Antonino Neri and Pierosandro Tagliaferri and Pierfrancesco Tassone",
year = "2013",
month = "6",
doi = "10.1517/14712598.2013.796356",
language = "English",
volume = "13",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Non-coding RNA

T2 - A novel opportunity for the personalized treatment of multiple myeloma

AU - Amodio, Nicola

AU - Di Martino, Maria Teresa

AU - Neri, Antonino

AU - Tagliaferri, Pierosandro

AU - Tassone, Pierfrancesco

PY - 2013/6

Y1 - 2013/6

N2 - Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.

AB - Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.

KW - MicroRNA

KW - MiRNA

KW - MiRNA therapeutics

KW - Multiple myeloma

KW - Non coding RNA

UR - http://www.scopus.com/inward/record.url?scp=84879592480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879592480&partnerID=8YFLogxK

U2 - 10.1517/14712598.2013.796356

DO - 10.1517/14712598.2013.796356

M3 - Article

C2 - 23692413

AN - SCOPUS:84879592480

VL - 13

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - SUPPL.1

ER -